Literature DB >> 9692438

Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass.

L A Brasil1, W J Gomes, R Salomão, E Buffolo.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha has been implicated in complications seen after cardiac operations with cardiopulmonary bypass. The release of tumor necrosis factor-alpha and its possible effects were studied in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.
METHODS: Twenty patients were studied, 10 with (group 1) and 10 without cardiopulmonary bypass (group 2). Serial blood samples were obtained before, during, and up to 48 hours after operation. Circulating tumor necrosis factor-alpha levels, leukocyte counts, and erythrocyte sedimentation rates were measured. Hemodynamic variables (blood pressure and heart rate), temperature, orotracheal intubation time, postoperative bleeding, and inotropic drug requirements were compared.
RESULTS: Serum levels of tumor necrosis factor-alpha were detected in 6 patients (60%) in group 1 and none in group 2. The patients in group 1 had more hypotension than those in group 2 (7.4 +/- 1.0 mm Hg versus 8.5 +/- 0.7 mm Hg), required more inotropic drugs (8 patients versus 1 patient), and had a higher heart rate (114 +/- 8 beats per minute versus 98 +/- 10 beats per minute), a higher temperature (37.1 degrees +/- 0.5 degrees C versus 36.6 degrees +/- 0.3 degrees C), increased postoperative bleeding (820 +/- 120 mL versus 360 +/- 84 mL), a longer orotracheal intubation time (13.6 +/- 2.2 hours versus 9.3 +/- 1.4 hours), and a more pronounced leukocytosis.
CONCLUSIONS: Cardiopulmonary bypass induces the whole-body inflammatory response through the release of tumor necrosis factor alpha, resulting in adverse systemic effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692438     DOI: 10.1016/s0003-4975(98)00181-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

1.  Combined coronary artery and abdominal aortic surgery without cardiopulmonary bypass.

Authors:  R Ascione; G Iannelli; N Spampinato
Journal:  Tex Heart Inst J       Date:  2000

Review 2.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

3.  Influence of the type of congenital heart defects on epithelial lining fluid composition in infants undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Manuela Simonato; Aldo Baritussio; Virgilio P Carnielli; Luca Vedovelli; Gianclaudio Falasco; Michele Salvagno; Massimo Padalino; Paola Cogo
Journal:  Pediatr Res       Date:  2018-02-07       Impact factor: 3.756

4.  Off-pump coronary artery bypass grafting attenuates proinflammatory markers.

Authors:  Atsushi Yamaguchi; Hidehito Endo; Koji Kawahito; Hideo Adachi; Takashi Ino
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-03

5.  Analysis of the Use of Extracorporeal Circulation on the In-Hospital Outcomes of Dialytic Patients Who Underwent Myocardial Revascularization Surgery.

Authors:  Matheus Miranda; João Nelson Rodrigues Branco; Guilherme Flora Vargas; Nelson Americo Hossne; Michele Costa Yoshimoto; José Honorio de Almeida Palma da Fonseca; José Osmar Medina de Abreu Pestana; Enio Buffolo
Journal:  Arq Bras Cardiol       Date:  2016-12       Impact factor: 2.000

6.  Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.

Authors:  Jeffrey S Berger; Peter M Herout; Qing Harshaw; Steven R Steinhubl; Carla B Frye; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 7.  Genetic susceptibility to inflammatory injury and various adverse outcomes.

Authors:  John M Murkin; Keith R Walley
Journal:  J Extra Corpor Technol       Date:  2009-03

8.  Cyclohexanone contamination from extracorporeal circuits impairs cardiovascular function.

Authors:  Caitlin S Thompson-Torgerson; Hunter C Champion; Lakshmi Santhanam; Z Leah Harris; Artin A Shoukas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-01       Impact factor: 4.733

9.  Lipopolysaccharide binding protein and sCD14 are not produced as acute phase proteins in cardiac surgery.

Authors:  Manuela Kudlova; Pavel Kunes; Martina Kolackova; Vladimir Lonsky; Jiri Mandak; Ctirad Andrys; Karolina Jankovicova; Jan Krejsek
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

10.  Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection.

Authors:  Tobias Walker; Hans P Wendel; Liane Tetzloff; Claudia Raabe; Olaf Heidenreich; Perikles Simon; Albertus M Scheule; Gerhard Ziemer
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.